Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Gut. 2021 Jun 14;71(6):1095–1105. doi: 10.1136/gutjnl-2021-324053

Figure 6. Host LCT genotype, milk intake, gut Bifidobacterium and serum indolepropionate.

Figure 6

(A) Adjusted means and 95% confidence intervals (CIs) of milk intake (servings/day) according to LCT-rs49883235 genotypes in the HCHS/SOL. (B) Adjusted means and 95% CIs of gut Bifidobacterium abundance (center log-ratio transformed) according to LCT-rs49883235 genotypes in the HCHS/SOL. (C) Adjusted means and 95% CIs of serum indolepropnate levels (inverse normal transformed) according to LCT-rs49883235 genotypes in the HCHS/SOL. (D) Adjusted means and 95% CIs of gut Bifidobacterium abundance (center log-ratio transformed) according to milk intake stratified by the LCT-rs49883235 genotype in the HCHS/SOL. (E) Adjusted means and 95% CIs of serum indolepropnate levels (inverse normal transformed) according to milk intake stratified by the LCT-rs49883235 genotype in the HCHS/SOL. (F) Differences and 95% CIs in serum indolepropnate levels (inverse normal transformed) associated with one serving per day of milk intake according to the LCT-rs49883235 genotype in the HCHS/SOL and ARIC separately, and combined by meta-analysis.